Abstracts tagged "myositis and rituximab"

Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Jutta Bauhammer¹, Norbert Blank², Hanns-Martin Lorenz³, Regina Max⁴, Dietmar Krause⁵ and Christoph Fiehn¹, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁴Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
Abstract Number: 2368 • 2015 ACR/ARHP Annual Meeting
Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Fernando Henrique Carlos de Souza¹, Renata Miossi², Julio C. B. Moraes¹, Karina Bonfiglioli¹, Eloisa Bonfá¹ and Samuel Katsuyuki Shinjo¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: The treatment of idiopathic inflammatory myopathies (IIM) is challenging, complicated by its rarity and heterogeneity. Currently few studies have suggested the efficacy of RTX…
Abstract Number: 1273 • 2014 ACR/ARHP Annual Meeting
Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome
Tracy Doyle¹, Juan Osorio², Eduarda Nilo DeMagaldi³, Rachna Madan⁴, Fernanda Cabral⁵, Ivan Rosas² and Paul Dellaripa⁶, ¹Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ²Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ³medicine, Harvard Medical School, Boston, MA, ⁴Radiology, Brigham and women's Hospital, Boston, MA, ⁵Radiiology, Brigham and women's Hospital, boston, MA, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/purpose: To assess clinical outcomes including pulmonary function and radiographic imaging in patients with ILD and the antisynthetase syndrome who were treated with Rituxan (RTX)Methods:…
Abstract Number: 914 • 2014 ACR/ARHP Annual Meeting
A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers
Jeannette Olazagasti¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla¹, Rohit Aggarwal³, Chester V. Oddis⁴ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory…
Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting
Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement – the RIM Study
Cynthia S. Crowson¹, Ann M. Reed², Molly Hein³, Abigail B. Green¹, Consuelo Lopez de Padilla⁴, Rohit Aggarwal⁵, Dana P. Ascherman⁶, Marc C. Levesque⁷ and Chester V. Oddis⁸, ¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].